Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 269

1.

Less Is More: The Evolving Surgical Approach to Breast Cancer.

Esserman L, Gallant E, Alvarado M.

Am Soc Clin Oncol Educ Book. 2016;35:e5-e10. doi: 10.14694/EDBK_159060.

2.

When Less Is Better, but Physicians Are Afraid Not to Intervene.

Esserman L.

JAMA Intern Med. 2016 May 31. doi: 10.1001/jamainternmed.2016.2257. [Epub ahead of print] No abstract available.

PMID:
27243587
3.

Proteomic Mapping of p53 Immunogenicity in Pancreatic, Ovarian, and Breast Cancers.

Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, Wallstrom G, LaBaer J, Cramer D, Hollingsworth MA, Anderson KS.

Proteomics Clin Appl. 2016 Apr 28. doi: 10.1002/prca.201500096. [Epub ahead of print]

PMID:
27121307
4.

Population-based screening for cancer: hope and hype.

Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ.

Nat Rev Clin Oncol. 2016 Apr 13. doi: 10.1038/nrclinonc.2016.50. [Epub ahead of print] Review.

PMID:
27071351
5.

When the Gold Standard Loses Its Luster, Perhaps It Is Time to Change Nomenclature.

Borowsky A, Esserman L.

Ann Intern Med. 2016 May 17;164(10):694-5. doi: 10.7326/M16-0526. Epub 2016 Mar 22. No abstract available.

PMID:
26999728
6.

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.

Esserman L, Yau C.

JAMA Oncol. 2016 Mar 1;2(3):395-6. doi: 10.1001/jamaoncol.2015.4840. No abstract available.

PMID:
26967177
7.

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.

Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM.

PLoS One. 2016 Feb 17;11(2):e0142047. doi: 10.1371/journal.pone.0142047. eCollection 2016.

8.

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN.

Breast Cancer Res Treat. 2016 Feb;155(3):521-30. doi: 10.1007/s10549-016-3701-7. Epub 2016 Feb 13.

PMID:
26875185
9.

Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?

Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L, Jatoi I, Brunt AM; MIAMI (Multiple Ipsilateral breast conserving surgery versus mastectomy) Trial Management Group.

Breast. 2016 Apr;26:149-50. doi: 10.1016/j.breast.2015.12.011. Epub 2016 Feb 3. No abstract available.

PMID:
26851965
10.

Detection of ductal carcinoma in situ and subsequent interval cancers.

Shieh Y, Eklund M, Esserman L.

BMJ. 2016 Feb 1;352:i551. doi: 10.1136/bmj.i551. No abstract available.

PMID:
26834245
11.

CLINICAL DECISIONS. Ductal Carcinoma In Situ.

Merrill AL, Esserman L, Morrow M.

N Engl J Med. 2016 Jan 28;374(4):390-2. doi: 10.1056/NEJMclde1512213. No abstract available.

12.

Outcomes Following Oncoplastic Reduction Mammoplasty: A Systematic Review.

Piper ML, Esserman LJ, Sbitany H, Peled AW.

Ann Plast Surg. 2016 May;76 Suppl 3:S222-6. doi: 10.1097/SAP.0000000000000720.

PMID:
26808743
13.

Neoadjuvant as Future for Drug Development in Breast Cancer--Response.

DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ; I-SPY2 Investigators.

Clin Cancer Res. 2016 Jan 1;22(1):269. doi: 10.1158/1078-0432.CCR-15-1643. No abstract available.

PMID:
26728411
14.

Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome.

Johnson J, Esserman L, Ewing C, Alvarado M, Park C, Fowble B.

Ann Surg Oncol. 2016 Mar;23(3):715-21. doi: 10.1245/s10434-015-4971-8. Epub 2015 Dec 29.

PMID:
26714943
15.

Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.

Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD; ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators.

Radiology. 2016 Apr;279(1):44-55. doi: 10.1148/radiol.2015150013. Epub 2015 Dec 1.

PMID:
26624971
16.

The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander-Implant Exchange in Prosthetic Breast Reconstruction.

Wang F, Peled AW, Chin R, Fowble B, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H.

Plast Reconstr Surg. 2016 Jan;137(1):1-9. doi: 10.1097/PRS.0000000000001866.

PMID:
26368331
17.

Rethinking the Standard for Ductal Carcinoma In Situ Treatment.

Esserman L, Yau C.

JAMA Oncol. 2015 Oct;1(7):881-3. doi: 10.1001/jamaoncol.2015.2607. No abstract available.

18.

How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.

Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ.

World J Clin Cases. 2015 Jul 16;3(7):607-13. doi: 10.12998/wjcc.v3.i7.607. Review.

19.

Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.

Wang F, Amara D, Peled AW, Sbitany H, Foster RD, Ewing CA, Alvarado M, Esserman LJ.

Ann Surg Oncol. 2015 Oct;22(10):3338-45. doi: 10.1245/s10434-015-4745-3. Epub 2015 Jul 28.

PMID:
26215194
20.

Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.

Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP.

Breast Cancer Res Treat. 2015 Aug;153(1):173-81. doi: 10.1007/s10549-015-3511-3. Epub 2015 Jul 25.

PMID:
26208485
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk